Utility of prognostic markers in second-line treatment of metastatic urothelial cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620565
Title:
Utility of prognostic markers in second-line treatment of metastatic urothelial cancer.
Authors:
Raby, Sophie; Conroy, Ruth; Lyons, Jeanette; Weaver, Jamie M J; Elliott, Tony ( 0000-0002-0715-9431 ) ; Choudhury, Ananya ( 0000-0002-3561-6580 )
Affiliation:
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Citation:
Utility of prognostic markers in second-line treatment of metastatic urothelial cancer. 2017 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
19-Aug-2017
URI:
http://hdl.handle.net/10541/620565
DOI:
10.1016/j.clon.2017.07.015
PubMed ID:
28830647
Type:
Article
Language:
en
ISSN:
1433-2981
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRaby, Sophieen
dc.contributor.authorConroy, Ruthen
dc.contributor.authorLyons, Jeanetteen
dc.contributor.authorWeaver, Jamie M Jen
dc.contributor.authorElliott, Tonyen
dc.contributor.authorChoudhury, Ananyaen
dc.date.accessioned2017-09-22T15:36:11Z-
dc.date.available2017-09-22T15:36:11Z-
dc.date.issued2017-08-19-
dc.identifier.citationUtility of prognostic markers in second-line treatment of metastatic urothelial cancer. 2017 Clin Oncolen
dc.identifier.issn1433-2981-
dc.identifier.pmid28830647-
dc.identifier.doi10.1016/j.clon.2017.07.015-
dc.identifier.urihttp://hdl.handle.net/10541/620565-
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleUtility of prognostic markers in second-line treatment of metastatic urothelial cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UKen
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.